Nevertheless, PI3K/AKT pathway activation in cancer can also be enhanced by mechanisms other than alterations in PIK3CA/AKT1/PTEN14,25,26, supported by preclinical data showing that capivasertib inhibited growth in some cell lines without PIK3CA/AKT1/PTEN alterations28. The gene discussed is PIK3CA; the disease is cancer.